HCA Healthcare, Inc. Revenue in 2025

HCA Healthcare, Inc. reported $74.3B in revenue for fiscal year 2025. This represents a growth of 5.2% compared to the 2024 figure of $70.6B.

$70.6 billion in annual revenue from operating hospitals in a business where the federal government is simultaneously your largest customer, your primary regulator, and your most aggressive prosecutor. The company carries $43.0 billion in total debt against $1.93 billion in cash, producing negative shareholders' equity of $2.5 billion. Its operating margin is 14.9%, its net margin 8.2%, and its adjusted EBITDA margin 19.7% — healthy by hospital industry standards but vulnerable to any disruption in reimbursement rates, volume trends, or labor costs. CEO Sam Hazen, who took the helm in 2020, has steered HCA through the COVID-19 pandemic, a post-pandemic volume recovery, and the operational challenges of Hurricanes Helene and Milton — which cost the company $250 million in 2024 — while maintaining a capital allocation strategy that returned $6.6 billion to shareholders through dividends and buybacks in 2024. HCA's 2025 guidance calls for revenue of $72.8 billion to $75.8 billion, net income of $5.85 billion to $6.29 billion, and adjusted EBITDA of $14.3 billion to $15.1 billion — targets that assume continued volume growth, stable payer mix, and the successful execution of a $400 million resiliency plan focused on AI-driven operational efficiency. HCA Healthcare, Inc. is the largest for-profit hospital operator in the United States, with FY2024 revenue of $70.6 billion, net income of $5.76 billion, and a market capitalization of approximately $82.6 billion. HCA returned $6.6 billion to shareholders through $6.04 billion in share repurchases and $599 million in dividends, while investing $4.9 billion in capital expenditures. The company carries $43.0 billion in total debt and maintains a target leverage range of 2.75x – 3.75x net debt to adjusted EBITDA. Founded in 1968 in Nashville, Tennessee, HCA survived the largest healthcare fraud settlement in US history ($1.7 billion in 2003), a record $33 billion leveraged buyout in 2006, and returned to public markets via a $3.8 billion IPO in 2011. In FY2024, inpatient services accounted for approximately 62.2% of revenue ($43.9 billion), while outpatient services contributed 37.8% ($26.7 billion). The payer mix in 2024 was estimated at 45% managed care/commercial insurance ($31.8 billion), 30% Medicare ($21.2 billion), 10% Medicaid ($7.1 billion), 8% self-pay/uninsured ($5.6 billion), and 7% other ($4.9 billion). The company's cost structure is dominated by labor, with salaries and benefits representing approximately 45.4% of revenue ($32.1 billion estimated for 2024). In 2024, capital expenditures totaled $4.9 billion, share repurchases were $6.04 billion, and dividends were $599 million. The company maintains a target leverage range of 2.75x – 3.75x net debt to adjusted EBITDA, using debt financing to fund growth while generating sufficient cash flow from operations ($10.5 billion in 2024) to service interest ($2.06 billion) and return capital to shareholders. $70.6 billion in annual revenue, $43 billion in debt, and negative shareholders' equity of $2.5 billion. Same-facility admissions grew 4.9%, revenue per equivalent admission increased 3.2%, and adjusted EBITDA grew 9.1% to $13.9 billion. The company returned $6.6 billion to shareholders while investing $4.9 billion in capital expenditures. CEO Sam Hazen has guided to continued growth in 2025, with revenue targeted at $74.3 billion and adjusted EBITDA at $14.7 billion. HCA Healthcare reported FY2024 revenue of $70.603 billion, an increase of 8.7% from $64.968 billion in 2023. Net income attributable to HCA Healthcare, Inc. Was $5.760 billion, or $22.00 per diluted share, compared to $5.242 billion, or $18.97 per diluted share, in 2023 — representing 9.9% net income growth. Operating income was $10.547 billion, producing an operating margin of 14.9%. Adjusted EBITDA totaled $13.882 billion, up 9.1% from $12.726 billion in 2023, with an adjusted EBITDA margin of 19.7%. Interest expense was $2.061 billion in 2024, up from $1.938 billion in 2023, reflecting the company's leveraged capital structure. Cash flow from operating activities totaled $10.514 billion, up 11.5% from $9.431 billion in 2023, demonstrating strong cash conversion. Capital expenditures were $4.9 billion, while share repurchases totaled $6.042 billion and dividends were $599 million — returning $6.6 billion to shareholders. The balance sheet carries $43.031 billion in total debt, $1.933 billion in cash, and negative shareholders' equity of $2.499 billion. Total assets were $59.513 billion. The net debt to adjusted EBITDA ratio was approximately 2.96x, within the company's target range of 2.75x – 3.75x. HCA's 2025 guidance calls for revenue of $72.8 billion to $75.8 billion (midpoint $74.3 billion, up 5.2%), net income of $5.85 billion to $6.29 billion (midpoint $6.07 billion, up 5.4%), adjusted EBITDA of $14.3 billion to $15.1 billion (midpoint $14.7 billion, up 5.9%), and diluted EPS of $24.05 to $25.85 (midpoint $24.95, up 13.4%). Capital expenditures are estimated at $5.0 billion to $5.2 billion. Q1 2026 revenue was $19.11 billion with net income of $1.62 billion. Fifth, supplemental Medicaid payment programs — which provided an incremental $400 million net benefit in 2024, exceeding prior expectations of $100 – $200 million — are unpredictable and subject to state budget pressures. For 2025, HCA has guided to a range from flat to a $250 million headwind from these programs, creating earnings volatility. Seventh, the company's extraordinary leverage — $43.0 billion in total debt, $41.1 billion net of cash, and negative shareholders' equity of $2.5 billion — creates financial vulnerability. Hurricanes Helene and Milton cost HCA $250 million in 2024, and the company's concentration in Florida (47 hospitals), Texas (45 hospitals), and the Gulf Coast exposes it to recurring hurricane risk. The $4.9 billion in 2024 capital expenditures and $5.0 – $5.2 billion guidance for 2025 represent investments in capacity expansion, de novo hospitals, and ambulatory facilities that strengthen market position. The company has a multi-year capital pipeline of $5.5 – $6 billion in approved projects, with 2025 capital expenditures guided at $5.0 – $5.2 billion. The second pillar, operational efficiency, targets $400 million in cost savings through a resiliency plan that leverages digital transformation and AI. In 2024, HCA deployed $4.9 billion in capital expenditures, $6.04 billion in share repurchases, and $599 million in dividends. The company has guided to a $0 – $250 million headwind from supplemental Medicaid payment programs in 2025, compared to a $400 million tailwind in 2024. The HCA-Columbia merger, completed in February 1994 in a stock swap valued at $5.7 billion, created Columbia/HCA — the largest hospital company in the United States. Revenues topped $19 billion, and Fortune magazine named Columbia/HCA the most admired healthcare company in 1997. Richard Scott was forced to resign in July 1997, receiving approximately $10 million in cash and $300 million in stock. Columbia/HCA pleaded guilty to 14 corporate felonies and paid a total of $1.7 billion in criminal fines and civil settlements, including $840 million in 2000 and $881 million in 2003. In July 2006, a consortium of Bain Capital, KKR, and Merrill Lynch Global Private Equity acquired HCA for approximately $33 billion — including $21 billion in equity and $11.7 billion in debt assumption — paying $51 per share, an 18% premium to the prior closing price. During private ownership, the company paid $4.25 billion in dividends to its backers in 2010 alone. HCA returned to public markets in March 2011 via an IPO that raised $3.8 billion, the largest private-equity-backed initial public offering in US history at the time. The IPO netted Bain Capital over $1 billion on an initial investment of just $64 million, generating a return exceeding 200%.